AI Summary
We reviewed 16 live results for skyrizi (risankizumab) 150mg and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Immunology and Biologics.
Comparison Table
Recommended
Skyrizi (risankizumab-rzaa)
Source: AbbVie Inc.
Description
Skyrizi is an FDA-approved prescription biologic medication and interleukin-23 (IL-23) inhibitor. It is used to treat adults with moderate-to-severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn's disease or ulcerative colitis. The medication is available in several forms, including a 150 mg/mL single-dose prefilled pen or syringe for subcutaneous injection, as well as an intravenous (IV) infusion for induction and an on-body injector for maintenance dosing. As a targeted immunology therapy, it helps reduce inflammation by blocking specific proteins in the body.
Best for
moderate-to-severe plaque psoriasis, active psoriatic arthritis, Crohn's disease management, ulcerative colitis treatment and biologic therapy seekers
View Details
Rating
Skyrizi (risankizumab) 150mg
Source: AbbVie Singapore
Description
Prescription biologic for the treatment of plaque psoriasis and psoriatic arthritis. The Singapore hub serves as a key regional reference for medical documentation and treatment guidelines for risankizumab therapies in Southeast Asia.
Best for
regional medical reference, Singapore-based patients and biologic therapy information
View Details
Rating
Skyrizi (risankizumab)
Source: AbbVie Pharmaceuticals (Thailand) Ltd.
Description
Skyrizi (risankizumab) is a prescription biological medication used to treat adults with moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. As an IL-23 inhibitor, it targets the p19 subunit to manage chronic inflammation and is administered via subcutaneous injection, typically requiring a maintenance dose every 12 weeks after initial loading.
Best for
plaque psoriasis patients, psoriatic arthritis management, Crohn's disease treatment and long-term biologic therapy
View Details
Rating
| Compare | Skyrizi (risankizumab-rzaa) | Skyrizi (risankizumab) 150mg | Skyrizi (risankizumab) |
|---|---|---|---|
| Source | AbbVie Inc. | AbbVie Singapore | AbbVie Pharmaceuticals (Thailand) Ltd. |
| Description | Skyrizi is an FDA-approved prescription biologic medication and interleukin-23 (IL-23) inhibitor. It is used to treat adults with moderate-to-severe plaque psoriasis, active psoriatic arthritis, and moderately to severely active Crohn's disease or ulcerative colitis. The medication is available in several forms, including a 150 mg/mL single-dose prefilled pen or syringe for subcutaneous injection, as well as an intravenous (IV) infusion for induction and an on-body injector for maintenance dosing. As a targeted immunology therapy, it helps reduce inflammation by blocking specific proteins in the body. | Prescription biologic for the treatment of plaque psoriasis and psoriatic arthritis. The Singapore hub serves as a key regional reference for medical documentation and treatment guidelines for risankizumab therapies in Southeast Asia. | Skyrizi (risankizumab) is a prescription biological medication used to treat adults with moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. As an IL-23 inhibitor, it targets the p19 subunit to manage chronic inflammation and is administered via subcutaneous injection, typically requiring a maintenance dose every 12 weeks after initial loading. |
| Best for | moderate-to-severe plaque psoriasis, active psoriatic arthritis, Crohn's disease management, ulcerative colitis treatment and biologic therapy seekers | regional medical reference, Singapore-based patients and biologic therapy information | plaque psoriasis patients, psoriatic arthritis management, Crohn's disease treatment and long-term biologic therapy |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Skyrizi (risankizumab-rzaa) from AbbVie Inc.."
I picked this because Skyrizi is the primary medication matching your search, specifically FDA-approved for multiple chronic inflammatory conditions and available in convenient self-injection formats.
Share this search
Related Finds